To direct the Secretary of Health and Human Services to enter into agreements with drug manufacturers to establish reserve supplies of covered pediatric cancer drugs, and for other purposes.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, To direct the Secretary of Health and Human Services to enter into agreements with drug manufacturers to establish reserve supplies of covered pediatric cancer drugs, and for other purposes., changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Government Operations, Environment.
Who Benefits and How
health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section HBC689D3A85024635BDCC6D038B98715E: 1. Short title This Act may be cited as the Pediatric Cancer Drug Supply Act of 2024.
- Section H6034ABA238CD4E2EA95DB21F31DC498E: 2. Establishment of essential pediatric cancer drug marketplace stability pilot program The Secretary shall carry out a pilot program under which the Secretary...
- Section HC5CF59A9E17F4F5E83EDDEA1507374BE: 3. Essential pediatric cancer drug list The Secretary, in consultation with the Commissioner of Food and Drugs and the Director of the National Cancer...
- Section H7155BB10F1764584BBBE6D330F99363F: 4. Distributions from essential pediatric cancer drug reserve supplies If a covered pediatric cancer drug is in shortage (as defined in section 506C(h) of the...
- Section HB711A45C76A6406EBC0A104DD9EB6BD1: 5. Reports to Congress For each year 1 or more drugs are held by a manufacturer in reserve supply pursuant to an agreement under section 2, the Secretary shall...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, To direct the Secretary of Health and Human Services to enter into agreements with drug manufacturers to establish reserve supplies of covered pediatric cancer drugs, and for other purposes., changes federal law or congressional policy affecting health care providers and patients.
Key Policy Areas
Healthcare, Government Operations, Environment
Primary Purpose
This bill, To direct the Secretary of Health and Human Services to enter into agreements with drug manufacturers to establish reserve supplies of covered pediatric cancer drugs, and for other purposes., changes federal law or congressional policy affecting health care providers and patients.
Policy Domains
Whole bill
Identified Gains
- health care providers and patients
Identified Costs
- federal implementing agencies
- health care providers and patients
Sponsors
Legislative Progress
IntroducedMs. Eshoo (for herself, Ms. DeGette, and Ms. Schrier) introduced …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_commission"
- → The commission identified in the operative section
- "secretary_of_health_and_human_services"
- → Secretary of Health and Human Services
Key Definitions
Terms defined in this bill
a facility— registered under section 510 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360)
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology